Meglumine iotalamate 600mg/ml (Iodine 280mg/ml) / Phenol 60mg/ml solution for injection 5ml ampoules

  Objective is an endemic disease. This study was done to compare the efficacy of intralesional meglumine antimoniate (MA) with combination of 50% trichloroacetic acid (TCA) and intralesional meglumine antimoniate in patients of cutaneous leishmaniasis (CL).   Methods It was a randomized controlled trial conducted in department of dermatology, Military Hospital, Rawalpindi over six months i.e. 02-08-2016 to 01-02-2017. A total of 210 patients (105 in each group) were taken in this study. Group A received 50% TCA fortnightly with intralesional meglumine antimoniate and group B was treated with intralesional meglumine antimoniate alone.   Results Efficacy was observed in 91 (86.7%) patients of group A and in 78 (74.3%) patients of group B (p=0.024).   Conclusion Combination therapy with TCA 50% and intralesional MA accelerated the resolution of CL lesions with significant difference in complete resolution rate in comparison to the patients treated with intralesional MA alone.  

Abstract licence: CC BY 4.0

Objective To compare the efficacy of combined parenteral Meglumine Antimoniate and oral Allopurinol with Meglumine Antimoniate alone in the treatment of Cutaneous Leishmaniasis. Study Design  Randomized controlled trial. Place and duration of study Department of Dermatology, Combined Military Hospital, Peshawar from May 2016- Oct 2016. Methods A total of 112 patients presenting with Cutaneous leishmaniasis were included in the study and randomly allocated in two groups. In group I participants received combined therapy with oral allopurinol 15mg/kg/day and parenteral meglumine antimoniate 15mg/kg/day while group II participants received only meglumine antimoniate 15mg/kg/day. Follow up was done at 8th week and results were recorded. Results  The mean age of the whole study sample was 27.4±4.6 years. In group I the efficacy was observed in 83.9% of patients compared to 73.2% in group II (p 0.167). Conclusion Our study concluded that the combination therapy (MA plus CL) is more effective in treating CL than isolation therapy with MA alone. More randomized controlled trials with larger sample sizes are highly recommended to draw more conclusive results and generate further evidence for uniform decision making in the treatment of CL.  

Abstract licence: CC BY 4.0

Objective: To evaluate the efficacy of the combination of oral allopurinol plus intralesional meglumine for thetreatment of Cutaneous Leishmaniasis.Study Design: A prospective study.Place and Duration of Study: The study was carried out at the Department of Dermatology, Combined MilitaryHospital, Multan, Pakistan from 18th September 2021 to 18th March 2022.Methods: The study was conducted on a total of 60 patients (30 in each group) who fulfilled the inclusioncriteria. Patients in group A were given oral allopurinol (15mg/kg/day) and intralesional meglumineantimoniate (2-5 ml). Patients in group B were given intralesional meglumine antimoniate (2-5 ml). All patientswere given 2 injections each week and were followed up for 8 weeks. The efficacy of the treatment was noted bythe disappearance of induration of the lesion and complete reepithelization of the ulcer. Healing wascharacterized by scar formation and was recorded.Results: Results showed that the cure rate in Group B was 16.6% (5), while in Group A it was 56.6% (17) (P<0.03).There was no significant difference in efficacy between both groups when stratified based on age, number oflesions per patient, and lesion location. However, the cure rate of ulcers and papules was significantly higher ingroup A compared to group B.Conclusion: It was concluded that the combination of intralesional meglumine antimoniate and oral allopurinolhas higher efficacy than intralesional meglumine antimoniate alone in the treatment of patients withcutaneous leishmaniasis. How to cite this: Qayyum N, Gul P, Zainab A, Jawaid M, Azam M, Sattar S. Comparison of Intralesional Meglumine Antimoniate Plus Oral Allopurinol with Intralesional Meglumine Antimoniate Alone for the Treatment of Cutaneous Leishmaniasis- A Prospective Study. 2024; 5(2): 181-186. doi: http://doi.org/10.37185/LnS.1.1.511

Abstract licence: CC BY-NC 4.0